Understanding United States Drug Pricing
Powerful Resources to Inform Pricing and Access Strategies
US drug pricing is undergoing a major transformation, driven by policy reforms including the Inflation Reduction Act and Most Favoured Nation (MFN) frameworks, and the rise of direct-to-consumer models. For pharmaceutical companies, this means greater pricing pressure, more complex access dynamics, and increased global spillover risk.
This is creating significant uncertainty across the industry. During our webinar “Most Favoured Nation: US Implementation and European Implications”, 56% of participants identified external reference pricing as a high risk to their products—highlighting rising concerns around the global impact of US pricing policies.
On this page, you will find expert insights and practical resources to help you navigate evolving US pricing dynamics, anticipate their impact, and make informed pricing and access decisions.
US Drug Pricing Expert Materials
Webinar
Watch this webinar to explore how MFN pricing may impact US drug prices, access in Europe, launch strategies, and biotech investment.
Cheat Sheet
Download this cheat sheet for a clear overview of how US drug pricing works today, and how emerging models may reshape the pricing landscape.
Article
Discover how dual branding strategies can mitigate international reference pricing pressure.
MFN Key Milestones Tracker
Given the pace of MFN policies evolution, understanding key milestones and timelines across the MFN models is challenging and critical to adapt your strategy early, and make informed decisions to reduce risk.
Below you will find a real-time tracker on the evolution of the GLOBE, GUARD, and GENEROUS models, helping you stay ahead of these developments.
US MFN policies are reshaping global pricing and access.
Is your strategy ready?
US MFN policies are reshaping global pricing and access. Is your strategy ready?
Anticipate MFN impact on your portfolio and upcoming launches and adapt early.
- Protect global revenue and minimize downside through licensing and business development decisions
- Refine launch sequencing and price corridor strategies across the US and EU
- Identify pricing vulnerabilities early with our MFN Navigator, a strategic stress-test to support decisions under CMS GLOBE and GUARD models